Amarin

An Irish subsidiary of Amarin Corp., which has its R&D operations in Stonington, has filed suit against fellow drug maker and AstraZeneca subsidiary Omthera Pharmaceuticals for patent infringement, it disclosed.

Irish biopharma Amarin Corp. PLC, whose R&D base is Stonington, said its fourth-quarter loss increased to $15.4 million on higher expenses.

Irish drug developer Amarin Corp., which has its research base in Stonington, said its CEO Joseph Zakrzewski is retiring and will be replaced by President John F. Thero.

Three top executives at Amarin Corp., which has its R&D base in Stonington, will receive special cash bonuses of $150,000 to $250,000 if the company can convince regulators to expand the patient pool that can be treated by its blood-fat drug Vascepa, according to a public filing.

Amarin Corp., which has its R&D base in Stonington, said the U.S. Food and Drug Administration has declined to accept its appeal of a decision late last month to rescind an agreement regarding its drug trial of Vascepa.

Irish drug developer Amarin Corp. PLC, whose research base is Stonington, won the blessing of federal drug regulators to contract with a South Korea company as a second global source of the active ingredient in its patented cardiovascular treatment, Vascepa, authorities say.

Irish biopharma Amarin Corp. PLC, whose R&D base is Stonington, says clinical trials for its synthetic omega-three fatty acid formulation has shown effectiveness in reducing a protein thought to slow the body's purging of heart-harmful compounds from the blood.

A pair of directors for Irish heart-drug developer Amarin Corp PLC, which has research operations in Stonington, is retiring from the board, effective this summer, a regulatory filing shows.

Amarin Corp. PLC lost money in the fourth quarter as the Irish drug developer with Stonington research and development operations continues to work in a synthetic fish-oil formulation to fight heart disease.

Amarin Corp. PLC, the Irish heart-drug developer with a research base in Stonington, won two more patents covering intellectual property contained in its proprietary synthetic fish-oil pill.